February 4, 2021 -- Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.
The vaccine is currently in phase III clinical development, and is the first to show efficacy against the original COVID-19 strain and the two variants emerging from the U.K. and South Africa, according to the firm.
The company will begin shipping the vaccine to Switzerland after the drug has undergone regulatory review, Novavax said.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: